Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Database
Language
Publication year range
1.
Cell Chem Biol ; 30(10): 1303-1312.e3, 2023 10 19.
Article in English | MEDLINE | ID: mdl-37506701

ABSTRACT

Transcription factor NF-κB potently activates anti-apoptotic genes, and its inactivation significantly reduces tumor cell survival following genotoxic stresses. We identified two structurally distinct lead compounds that selectively inhibit NF-κB activation by DNA double-strand breaks, but not by other stimuli, such as TNFα. Our compounds do not directly inhibit previously identified regulators of this pathway, most critically including IκB kinase (IKK), but inhibit signal transmission in-between ATM, PARP1, and IKKγ. Deconvolution strategies, including derivatization and in vitro testing in multi-kinase panels, yielded shared targets, cdc-like kinase (CLK) 2 and 4, as essential regulators of DNA damage-induced IKK and NF-κB activity. Both leads sensitize to DNA damaging agents by increasing p53-induced apoptosis, thereby reducing cancer cell viability. We propose that our lead compounds and derivatives can be used in context of genotoxic therapy-induced or ongoing DNA damage to increase tumor cell apoptosis, which may be beneficial in cancer treatment.


Subject(s)
NF-kappa B , Signal Transduction , NF-kappa B/metabolism , DNA Damage , Gene Expression Regulation , DNA
2.
Development ; 148(21)2021 11 01.
Article in English | MEDLINE | ID: mdl-34751748

ABSTRACT

Although the role of the transcription factor NF-κB in intestinal inflammation and tumor formation has been investigated extensively, a physiological function of NF-κB in sustaining intestinal epithelial homeostasis beyond inflammation has not been demonstrated. Using NF-κB reporter mice, we detected strong NF-κB activity in Paneth cells, in '+4/+5' secretory progenitors and in scattered Lgr5+ crypt base columnar stem cells of small intestinal (SI) crypts. To examine NF-κB functions in SI epithelial self-renewal, mice or SI crypt organoids ('mini-guts') with ubiquitously suppressed NF-κB activity were used. We show that NF-κB activity is dispensable for maintaining SI epithelial proliferation, but is essential for ex vivo organoid growth. Furthermore, we demonstrate a dramatic reduction of Paneth cells in the absence of NF-κB activity, concomitant with a significant increase in goblet cells and immature intermediate cells. This indicates that NF-κB is required for proper Paneth versus goblet cell differentiation and for SI epithelial homeostasis, which occurs via regulation of Wnt signaling and Sox9 expression downstream of NF-κB. The current study thus presents evidence for an important role for NF-κB in intestinal epithelial self-renewal.


Subject(s)
Goblet Cells/cytology , Intestine, Small/cytology , NF-kappa B/metabolism , Paneth Cells/cytology , Animals , Cell Differentiation , Cell Self Renewal , Goblet Cells/metabolism , Homeostasis , Intestinal Mucosa/cytology , Intestinal Mucosa/metabolism , Intestine, Small/metabolism , Intestine, Small/pathology , Mice , NF-kappa B/genetics , Organoids/cytology , Organoids/growth & development , Organoids/metabolism , Paneth Cells/metabolism , SOX9 Transcription Factor/metabolism , Stem Cells/cytology , Stem Cells/metabolism , Wnt Proteins/metabolism , Wnt Signaling Pathway
3.
Protein Cell ; 9(2): 216-237, 2018 02.
Article in English | MEDLINE | ID: mdl-28748451

ABSTRACT

The tricarboxylic acid (TCA) cycle is a central route for oxidative phosphorylation in cells, and fulfills their bioenergetic, biosynthetic, and redox balance requirements. Despite early dogma that cancer cells bypass the TCA cycle and primarily utilize aerobic glycolysis, emerging evidence demonstrates that certain cancer cells, especially those with deregulated oncogene and tumor suppressor expression, rely heavily on the TCA cycle for energy production and macromolecule synthesis. As the field progresses, the importance of aberrant TCA cycle function in tumorigenesis and the potentials of applying small molecule inhibitors to perturb the enhanced cycle function for cancer treatment start to evolve. In this review, we summarize current knowledge about the fuels feeding the cycle, effects of oncogenes and tumor suppressors on fuel and cycle usage, common genetic alterations and deregulation of cycle enzymes, and potential therapeutic opportunities for targeting the TCA cycle in cancer cells. With the application of advanced technology and in vivo model organism studies, it is our hope that studies of this previously overlooked biochemical hub will provide fresh insights into cancer metabolism and tumorigenesis, subsequently revealing vulnerabilities for therapeutic interventions in various cancer types.


Subject(s)
Citric Acid Cycle/drug effects , Molecular Targeted Therapy/methods , Neoplasms/drug therapy , Neoplasms/metabolism , Animals , Humans , Neoplasms/genetics , Neoplasms/pathology , Oncogenes/genetics , Tumor Suppressor Proteins/metabolism
4.
Mol Metab ; 7: 119-131, 2018 01.
Article in English | MEDLINE | ID: mdl-29129613

ABSTRACT

OBJECTIVE: Peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) promotes hepatic gluconeogenesis by activating HNF4α and FoxO1. PGC-1α expression in the liver is highly elevated in obese and diabetic conditions, leading to increased hepatic glucose production. We previously showed that the spliced form of X-box binding protein 1 (XBP1s) suppresses FoxO1 activity and hepatic gluconeogenesis. The shared role of PGC-1α and XBP1s in regulating FoxO1 activity and gluconeogenesis led us to investigate the probable interaction between PGC-1α and XBP1s and its role in glucose metabolism. METHODS: We investigated the biochemical interaction between PGC-1α and XBP1s and examined the role of their interaction in glucose homeostasis using animal models. RESULTS: We show that PGC-1α interacts with XBP1s, which plays an anti-gluconeogenic role in the liver by suppressing FoxO1 activity. The physical interaction between PGC-1α and XBP1s leads to suppression of XBP1s activity rather than its activation. Upregulating PGC-1α expression in the liver of lean mice lessens XBP1s protein levels, and reducing PGC-1α levels in obese and diabetic mouse liver restores XBP1s protein induction. CONCLUSIONS: Our findings reveal a novel function of PGC-1α as a suppressor of XBP1s function, suggesting that hepatic PGC-1α promotes gluconeogenesis through multiple pathways as a co-activator for HNF4α and FoxO1 and also as a suppressor for anti-gluconeogenic transcription factor XBP1s.


Subject(s)
Gluconeogenesis , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , X-Box Binding Protein 1/metabolism , Animals , Cell Line , Cells, Cultured , Forkhead Box Protein O1/metabolism , Homeostasis , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics , Protein Binding , X-Box Binding Protein 1/genetics
5.
Cell ; 167(4): 1052-1066.e18, 2016 11 03.
Article in English | MEDLINE | ID: mdl-27814504

ABSTRACT

It is widely believed that inflammation associated with obesity has an important role in the development of type 2 diabetes. IκB kinase beta (IKKß) is a crucial kinase that responds to inflammatory stimuli such as tumor necrosis factor α (TNF-α) by initiating a variety of intracellular signaling cascades and is considered to be a key element in the inflammation-mediated development of insulin resistance. We show here, contrary to expectation, that IKKß-mediated inflammation is a positive regulator of hepatic glucose homeostasis. IKKß phosphorylates the spliced form of X-Box Binding Protein 1 (XBP1s) and increases the activity of XBP1s. We have used three experimental approaches to enhance the IKKß activity in the liver of obese mice and observed increased XBP1s activity, reduced ER stress, and a significant improvement in insulin sensitivity and consequently in glucose homeostasis. Our results reveal a beneficial role of IKKß-mediated hepatic inflammation in glucose homeostasis.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Endoplasmic Reticulum Stress , Glucose/metabolism , I-kappa B Kinase/metabolism , X-Box Binding Protein 1/metabolism , Animals , Cell Line, Tumor , Homeostasis , Humans , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Obesity/metabolism , Phosphorylation , Protein Stability
6.
Am J Pathol ; 186(11): 2803-2812, 2016 11.
Article in English | MEDLINE | ID: mdl-27751443

ABSTRACT

The vasculature influences the progression and resolution of tissue inflammation. Capillaries express vascular endothelial growth factor (VEGF) receptors, including neuropilins (NRPs), which regulate interstitial fluid flow. NRP2, a receptor of VEGFA and semaphorin (SEMA) 3F ligands, is expressed in the vascular and lymphatic endothelia. Previous studies have demonstrated that blocking VEGF receptor 2 attenuates VEGFA-induced vascular permeability. The inhibition of NRP2 was hypothesized to decrease vascular permeability as well. Unexpectedly, massive tissue swelling and edema were observed in Nrp2-/- mice compared with wild-type littermates after delayed-type hypersensitivity reactions. Vascular permeability was twofold greater in inflamed blood vessels in Nrp2-deficient mice compared to those in Nrp2-intact littermates. The addition of exogenous SEMA3F protein inhibited vascular permeability in Balb/cJ mice, suggesting that the loss of endogenous Sema3F activity in the Nrp2-deficient mice was responsible for the enhanced vessel leakage. Functional lymphatic capillaries are necessary for draining excess fluid after inflammation; however, Nrp2-mutant mice lacked superficial lymphatic capillaries, leading to 2.5-fold greater fluid retention and severe lymphedema after inflammation. In conclusion, Nrp2 deficiency increased blood vessel permeability and decreased lymphatic vessel drainage during inflammation, highlighting the importance of the NRP2/SEMA3F pathway in the modulation of tissue swelling and resolution of postinflammatory edema.


Subject(s)
Lymphedema/genetics , Membrane Proteins/metabolism , Nerve Tissue Proteins/metabolism , Neuropilin-2/deficiency , Vascular Endothelial Growth Factor A/metabolism , Animals , Blood Vessels/physiopathology , Capillary Permeability , Female , Humans , Inflammation/genetics , Inflammation/physiopathology , Lymphatic Vessels/physiopathology , Lymphedema/physiopathology , Membrane Proteins/genetics , Mice , Mice, Inbred BALB C , Nerve Tissue Proteins/genetics , Neuropilin-2/genetics , Neuropilin-2/metabolism , Specific Pathogen-Free Organisms , Vascular Endothelial Growth Factor A/genetics
7.
Nat Med ; 22(9): 1023-32, 2016 09.
Article in English | MEDLINE | ID: mdl-27479085

ABSTRACT

The increasing global prevalence of obesity and its associated disorders points to an urgent need for the development of novel and effective therapeutic strategies that induce healthy weight loss. Obesity is characterized by hyperleptinemia and central leptin resistance. In an attempt to identify compounds that could reverse leptin resistance and thus promote weight loss, we analyzed a library of small molecules that have mRNA expression profiles similar to that of celastrol, a naturally occurring compound that we previously identified as a leptin sensitizer. Through this process, we identified another naturally occurring compound, withaferin A, that also acts as a leptin sensitizer. We found that withaferin-A treatment of mice with diet-induced obesity (DIO) resulted in a 20-25% reduction of body weight, while also decreasing obesity-associated abnormalities, including hepatic steatosis. Withaferin-A treatment marginally affected the body weight of ob/ob and db/db mice, both of which are deficient in leptin signaling. In addition, withaferin A, unlike celastrol, has beneficial effects on glucose metabolism that occur independently of its leptin-sensitizing effect. Our results show that the metabolic abnormalities of DIO can be mitigated by sensitizing animals to endogenous leptin, and they indicate that withaferin A is a potential leptin sensitizer with additional antidiabetic actions.


Subject(s)
Blood Glucose/drug effects , Body Weight/drug effects , Diabetes Mellitus, Type 2/metabolism , Diet, High-Fat , Fatty Liver/metabolism , Leptin/metabolism , Liver/drug effects , Obesity/metabolism , Withanolides/pharmacology , Animals , Blood Glucose/metabolism , Blotting, Western , Fatty Liver/pathology , Fluorescent Antibody Technique , Glucose Tolerance Test , Hypothalamus/drug effects , Hypothalamus/metabolism , Immunohistochemistry , Liver/metabolism , Liver/pathology , Mice , Mice, Obese , Pentacyclic Triterpenes , Real-Time Polymerase Chain Reaction , STAT3 Transcription Factor/drug effects , STAT3 Transcription Factor/metabolism , Signal Transduction , Triterpenes/pharmacology
8.
Arch Environ Occup Health ; 71(5): 293-299, 2016 Sep 02.
Article in English | MEDLINE | ID: mdl-26394928

ABSTRACT

The objectives of this study were to assess the nutritional status, daily energy intake, and daily energy expenditure of coal miners in Turkey. A total of 135 healthy coal miners (aged 19-64 years) were evaluated. Heart rates were measured using Polar watches, and the total energy expenditure was calculated using physical activity level formula and Hiilloskorpi equation. The average body mass index of the participants was 25.7 ± 3.98 kg/m2, and the average energy intake was 3,973.7 ± 420.85 kcal. According to Dietary Reference Intakes, the energy and nutrient intakes of the miners were adequate, except for the intake of vitamin D. The coal miners were found to be at moderate (43.0%), heavy (41.5%), and very heavy (13.3%) activity levels. Calculations of the energy expenditure at work were found to be 2,189.8 ± 376.19 to 2,788.8 ± 359.89 kcal per day. Further studies have to be conducted for developing national standards for each occupation.


Subject(s)
Energy Intake , Energy Metabolism , Miners , Nutritional Status , Occupational Health , Adult , Coal , Cross-Sectional Studies , Humans , Male , Middle Aged , Miners/statistics & numerical data , Turkey , Young Adult
9.
Microvasc Res ; 96: 68-76, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25087623

ABSTRACT

Metastasis is the leading cause of cancer-related deaths. Understanding how the lymphatic system responds to its environment and local stimuli may lead to therapies to combat metastasis and other lymphatic-associated diseases. This review compares lymphatic vessels and blood vessels, discusses markers of lymphatic vasculature, and elucidates some of the signaling motifs involved in lymphangiogenesis. Recent progress implicating the neuropilin and semaphorin axes in this process is discussed.


Subject(s)
Lymphangiogenesis/physiology , Neoplasm Metastasis/physiopathology , Neuropilins/physiology , Semaphorin-3A/physiology , Animals , Humans , Lymphatic Metastasis , Lymphatic System/pathology , Lymphatic Vessels/pathology , Mice , Mice, Inbred BALB C , Mice, Transgenic , Mutation , Neoplasms/blood supply , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL